Dr. Albertini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-262-1982
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1991- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1984 - 1986
University of Vermont College of MedicineClass of 1984
Certifications & Licensure
WI State Medical License 1985 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2008-2013
Clinical Trials
- Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma Start of enrollment: 1999 May 01
- Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma Start of enrollment: 2005 May 01
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma Start of enrollment: 2007 Dec 17
- Join now to see all
Publications & Presentations
PubMed
- 166 citationsMelanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN GuidelinesSusan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel M. Baumgartner
Journal of the National Comprehensive Cancer Network. 2021-04-01 - 6 citationsNeutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.Vincent Pozorski, Yeonhee Park, Yusuf Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo
Pigment Cell & Melanoma Research. 2023-11-01 - 320 citationsEffect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical TrialRichard D. Carvajal, Jeffrey A. Sosman, Jorge F. Quevedo, Mohammed M. Milhem, Anthony M. Joshua
JAMA. 2014-06-18
Journal Articles
- The Age of Enlightenment in Melanoma ImmunotherapyMark Albertini, MD, BioMed Central
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Press Mentions
New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against ThemselvesOctober 23rd, 2019
Wisconsin Physicians Honored for Cross-Specialty Collaboration to Advance Skin Cancer TreatmentSeptember 18th, 2019- The Age of Melanoma EnlightenmentAugust 16th, 2018
- Join now to see all
Grant Support
- Clinical Academic Oncologist Training ProgramNational Cancer Institute2006–2008
- Vaccine Therapy AND/OR GM-CSF In Locally Advanced Or Metastatic MelanomaNational Center For Research Resources2006–2007
- High-Dose Ifn-Alpha-2b VS Cisplatin, Vinblastine, DTIC + IL-2 &Ifn In MelanomaNational Center For Research Resources2006–2007
- Phase I/IB Trial Of Hu14 18 IL 2 Fusion Protein In Patients W/ Gd2+ TNational Center For Research Resources1999–2002
- Immunization Using Particle Mediated Transfer Of GenesNational Center For Research Resources2000
- Phase I Ch14.18 And R24 MOAB And IL-2 For Patients With Gd2+/Gd3+National Center For Research Resources1996–1999
- Gene Therapy Of Melanoma By Particle BombardmentNational Cancer Institute1995–1999
- Tumor Infiltrating Lymphocytes In Breast Cancer EffusionNational Cancer Institute1987–1989
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
